Gsk (GSK) Common Equity (2016 - 2025)
Historic Common Equity for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $21.3 billion.
- Gsk's Common Equity rose 2157.22% to $21.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 billion, marking a year-over-year increase of 2157.22%. This contributed to the annual value of $16.7 billion for FY2024, which is 76.02% up from last year.
- As of Q3 2025, Gsk's Common Equity stood at $21.3 billion, which was up 2157.22% from $19.1 billion recorded in Q2 2025.
- In the past 5 years, Gsk's Common Equity ranged from a high of $36.0 billion in Q1 2022 and a low of $10.3 billion during Q3 2022
- For the 5-year period, Gsk's Common Equity averaged around $20.2 billion, with its median value being $17.4 billion (2024).
- As far as peak fluctuations go, Gsk's Common Equity crashed by 6573.8% in 2022, and later surged by 5560.69% in 2023.
- Gsk's Common Equity (Quarter) stood at $20.3 billion in 2021, then plummeted by 38.75% to $12.4 billion in 2022, then skyrocketed by 33.26% to $16.6 billion in 2023, then grew by 1.39% to $16.8 billion in 2024, then grew by 26.52% to $21.3 billion in 2025.
- Its Common Equity was $21.3 billion in Q3 2025, compared to $19.1 billion in Q2 2025 and $17.2 billion in Q1 2025.